Drug intelligence / Profile preview

CTH-601

Development stage: Preclinical
Lead developer: Cartherics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

CTH-601 is a preclinical, off-the-shelf induced pluripotent stem cell-derived CAR-NK cell therapy developed by Cartherics for ovarian cancer and endometriosis. The engineered NK cells express a chimeric antigen receptor directed against tumor-associated glycoprotein 72, enabling recognition and cytotoxic elimination of TAG-72-expressing cells. Cartherics lists the program as preclinical, with a planned pre-IND milestone in 2027.

Targets

TAG-72

Beyond the preview

Go deeper on CTH-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH-601.